Submitted by Anonymous (not verified) on 11 July 2024 - 11:02
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 4, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 4, Status: Authorised